Brian Kaspar

Brian Kaspar has held various roles throughout their work experience. Brian is currently serving as the Chief Scientific Officer at Insmed Incorporated since August 2021. Additionally, they are a Board Member at AccuGen Group and a Scientific Advisory Board Member and Board of Directors at Endsulin, both since January 2021. In the past, Brian was the Scientific Founder of Milo Biotechnology, a company focused on developing therapies for muscular disorders, starting in 2010. Brian also held the position of Chief Scientific Officer and Senior Vice President at AveXis Inc., a gene therapy company, from October 2012 to August 2019 when it was acquired by Novartis. Prior to that, they worked as a Professor of Pediatrics and Faculty at The Research Institute at Nationwide Children's Hospital from August 2004 to November 2017. Brian began their career as a Research Fellow and later a Research Grad and Postdoctoral Fellow at the Salk Institute for Biological Studies from 1998 to 2004.

Brian Kaspar holds a Ph.D. in Molecular Pathology from UC San Diego. Prior to their Ph.D., they completed a Bachelor of Science (B.S.) degree in Neurobiology and Neurosciences from the University of Illinois Urbana-Champaign.